On November 25, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported it will present positive biomarker and survival data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS ) taking place December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Positive clinical data from our Phase 2 study, together with differentiated biomarker findings from our Phase 3 program reinforce our confidence in our pivotal Phase 3 study in metastatic breast cancer," stated William V. Williams, MD, BriaCell’s President & CEO. "Together with our pipeline of novel off-the-shelf cell-based immunotherapies, we remain committed to advancing breakthroughs in cancer immunotherapy as we work to improve survival and clinical outcomes in cancer patients with unmet medical needs."
"Our biomarker data provides important insights into the mechanism of action of our novel immunotherapy with the goal of delivering more precisely targeted treatment options for oncologists, physicians, and patients," commented Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer.
Late-Breaking Abstract Number: 3688
Presentation Number: PS1-13-22
Presentation Title: Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM – 2:00 PM CST
Late-Breaking Abstract Number: 3713
Presentation Number: PS1-13-23
Presentation Title: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM – 2:00 PM CST
Abstract Number: 1614
Presentation Number: PS2-09-03
Presentation Title: Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer.
Poster Presentation Date/Time: Wednesday, December 10, 2025, 5:00 PM – 6:30 PM CST
Copies of the abstracts and posters will be made available at View Source
(Press release, BriaCell Therapeutics, NOV 25, 2025, View Source [SID1234661339])